A
Avidity Biosciences, Inc. (RNA)
NMS – Real Time Price. Currency in USD
13.23
+0.13 (0.99%)
At close: Mar 27, 2026, 4:00 PM EDT
13.23
0.00 (0.00%)
After-hours: Mar 27, 2026, 4:10 PM EDT
Get all premium features to the best stock analysis tool
NMS – Real Time Price. Currency in USD
13.23
+0.13 (0.99%)
At close: Mar 27, 2026, 4:00 PM EDT
13.23
0.00 (0.00%)
After-hours: Mar 27, 2026, 4:10 PM EDT
No Data
There are no news for this stock.
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 9.20 | 6.05 | 10 | |
| Quick ratio | 9.20 | 5.63 | 10 | |
| Debt to Equity | 0.03 | 0.30 | 9.0 | |
| Debt to Assets | 0.03 | 1.04 | 9.0 | |
| Interest coverage | N/A | -16.91 | 1.0 | |
| Weighted average score | 7.8 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 9M | 10M | 11M | 19M | 19M |
| Gross Profit | 8M | 7M | 8M | 15M | 15M |
| Operating Income | -179M | -236M | -379M | -746M | -746M |
| Net Income | -174M | -212M | -322M | -685M | -685M |
| EBITDA | -178M | -233M | -376M | -742M | -742M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | 65.6 | -39.93 | 5.5 |
| Next quarter | -31.13 | -6.55 | 1.0 |
| Current year | N/A | N/A | 1.0 |
| Next year | 1227.61 | 20.43 | 10 |
| Weighted average score | 4.4 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | -93.1 | -35.91 | N/A | -11.72 | 1.0 |
| Y/Y | -71.06 | -131.86 | N/A | -68.88 | 1.0 |
| 3y average | 29.91 | -62.07 | 6.78 | -84.63 | 4.3 |
| 5y average | 25.21 | -79.93 | -10.65 | -90.58 | 3.3 |
| Weighted average score | 2.4 | ||||
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | Wide | 8.0 |
| Switching costs | Medium | 5.0 |
| Network effect | None | 1.0 |
| Economies of scale | Narrow | 3.0 |
| Weighted average score | 3.6 | |
Company's cash reserves $382.5M significantly exceed its total debt $49.3M, ensuring strong financial flexibility
Total current assets $1.8B exceed Total current liabilities $195.4M, highlighting excellent liquidity
Debt-to-equity ratio (0.0) is well below the industry average (0.3), showcasing prudent financial management
Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns
Negative free cash flow -$175.3M limits the company's ability to reinvest or pay down debt